Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates

Area of Science:

• Pharmacology
• Oncology
• Translational Medicine

Background:

• MP470 is a multi-targeted tyrosine kinase inhibitor targeting key mutations in various cancers.
• It demonstrates potent in vitro and in vivo anticancer activity.
• Understanding its pharmacokinetic profile, particularly in the central nervous system, is crucial for clinical application.

Purpose of the Study:

• To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics of MP470.
• To assess CSF penetration in a non-human primate model predictive of human pharmacokinetics.

Main Methods:

• Oral administration of MP470 (300 mg) to non-human primates.
• Serial blood and CSF sampling for pharmacokinetic analysis.
• Quantification of MP470 concentrations using LC-MS/MS assay.

Main Results:

• MP470 achieved a plasma area under the curve (AUC) of 1,690 ± 821 nM h with a half-life of 11.0 ± 3.4 h.
• No measurable MP470 concentrations were detected in the cerebrospinal fluid (CSF).

Conclusions:

• MP470 exhibits minimal penetration into the CSF.
• Despite limited CSF exposure, its potent anticancer activity supports continued clinical investigation.